Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | SYRE Spyre Therapeutics, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $93.28 +4.8% | $16.02 -1.8% |
| StockIQ Score | 58C Moderate Risk: Medium | 42D Weak Risk: Medium |
| Technical | 70B | 36F |
| Fundamental | 46D+ | 35F |
| Growth | 58C | 50C- |
| Fair Value | 50C- | 38F |
| News | 86A | 50C- |
| Quality | 42D | 50C- |
| Risk | 48D+ | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Spyre Therapeutics (SYRE) outperforms Ascentage Pharma (AAPG) in most categories. SYRE has a stronger investor score (58 vs. 42), higher technical (70 vs. 36) and fundamental scores (46 vs. 35), and a moderate rating, while AAPG is rated weak. SYRE’s valuation score (50) also exceeds AAPG’s (38), though growth scores are close (58 vs. 50). SYRE shows broader strength across metrics.
